198 related articles for article (PubMed ID: 33264449)
1. Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression.
Gran C; Luong V; Bruchfeld JB; Liwing J; Afram G; Lund J; Usmani S; Alici E; Nahi H
Am J Hematol; 2021 Mar; 96(3):E63-E65. PubMed ID: 33264449
[No Abstract] [Full Text] [Related]
2. Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.
Bujarski S; Goldwater MS; Regidor BS; Jew S; Daniely D; Swift RA; Eades BM; Emamy-Sadr M; Souther E; Li M; Wang C; Xu N; Chen H; Spektor TM; Berenson JR
Eur J Haematol; 2021 Sep; 107(3):318-323. PubMed ID: 33993536
[TBL] [Abstract][Full Text] [Related]
3. New strategies for MGUS and smoldering multiple myeloma.
Kyle RA
Clin Adv Hematol Oncol; 2004 Aug; 2(8):507, 509. PubMed ID: 16163229
[No Abstract] [Full Text] [Related]
4. Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma.
Atrash S; Robinson M; Slaughter D; Aneralla A; Brown T; Robinson J; Ndiaye A; Sprouse C; Zhang Q; Symanowski JT; Friend R; Voorhees PM; Usmani SZ; Bhutani M
Blood Cancer J; 2018 Nov; 8(11):107. PubMed ID: 30410066
[No Abstract] [Full Text] [Related]
5. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.
Wu V; Moshier E; Leng S; Barlogie B; Cho HJ; Jagannath S; Madduri D; Mazumdar M; Parekh S; Chari A
Blood Adv; 2018 Jun; 2(12):1470-1479. PubMed ID: 29945937
[TBL] [Abstract][Full Text] [Related]
6. Reference change values of M-protein, free light chain and immunoglobulins in monoclonal gammopathy.
Evliyaoglu O; van Helden J; Jaruschewski S; Imöhl M; Weiskirchen R
Clin Biochem; 2019 Dec; 74():42-46. PubMed ID: 31526775
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used.
Bossuyt X; Delforge M; Reynders M; Dillaerts D; Sprangers B; Fostier K; Poesen K; Vercammen M
Leukemia; 2018 Aug; 32(8):1815-1818. PubMed ID: 29674643
[No Abstract] [Full Text] [Related]
8. The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma.
Bergón E; Miravalles E; Bergón E; Miranda I; Bergón M
Clin Chem Lab Med; 2005; 43(1):32-7. PubMed ID: 15653439
[TBL] [Abstract][Full Text] [Related]
9. The cut-offs for kappa/lambda ratio in bone marrow immunohistochemistry for the diagnosis of multiple myeloma.
Warnnissorn AN; Treetipsatit J; Limvorapitak W
Hematology; 2020 Dec; 25(1):292-298. PubMed ID: 32772824
[No Abstract] [Full Text] [Related]
10. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma.
Aljama MA; Sidiqi MH; Lakshman A; Dispenzieri A; Jevremovic D; Gertz MA; Lacy MQ; Buadi FK; Dingli D; Muchtar E; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Warsame R; Kourelis TV; Hwa YL; Kapoor P; Leung N; Go RS; Kyle RA; Rajkumar SV; Kumar SK
Blood Adv; 2018 Nov; 2(22):3149-3154. PubMed ID: 30463914
[TBL] [Abstract][Full Text] [Related]
11. A Rapidly Deteriorating Patient with Gross Increase in Serum Free Light Chains.
Fung AWS; Kohlhagen MC; DeMarco ML; Mills JR
Clin Chem; 2019 Sep; 65(9):1084-1088. PubMed ID: 31481352
[No Abstract] [Full Text] [Related]
12. Cutaneous Nodules in Multiple Myeloma. Cutaneous plasmacytoma associated with multiple myeloma.
Gómez-Armayones S; Climent F; Servitje O
Actas Dermosifiliogr; 2015 Sep; 106(7):581-2. PubMed ID: 25935193
[No Abstract] [Full Text] [Related]
13. Auer rod-like inclusions in κ light chain myeloma.
Noujaim JC; D'Angelo G
Blood; 2013 Oct; 122(17):2932. PubMed ID: 24312947
[No Abstract] [Full Text] [Related]
14. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.
Lakshman A; Rajkumar SV; Buadi FK; Binder M; Gertz MA; Lacy MQ; Dispenzieri A; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
Blood Cancer J; 2018 Jun; 8(6):59. PubMed ID: 29895887
[TBL] [Abstract][Full Text] [Related]
15. Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression.
Fernández de Larrea C; Isola I; Pereira A; Cibeira MT; Magnano L; Tovar N; Rodríguez-Lobato LG; Calvo X; Aróstegui JI; Díaz T; Lozano E; Rozman M; Yagüe J; Bladé J; Rosiñol L
Leukemia; 2018 Jun; 32(6):1427-1434. PubMed ID: 29463830
[TBL] [Abstract][Full Text] [Related]
16. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma.
Abraham RS; Clark RJ; Bryant SC; Lymp JF; Larson T; Kyle RA; Katzmann JA
Clin Chem; 2002; 48(4):655-7. PubMed ID: 11901068
[No Abstract] [Full Text] [Related]
17. Coexistence of myelodysplastic syndrome and multiple myeloma.
Tsiara S; Economou G; Panteli A; Isaakidis P; Kapsali E; Bourantas KL
J Exp Clin Cancer Res; 1999 Dec; 18(4):565-6. PubMed ID: 10746986
[TBL] [Abstract][Full Text] [Related]
18. The pattern of the M-protein in smoldering myeloma over the time: an evolving risk factor.
Fernández de Larrea C; Isola I; Pereira A; Cibeira MT; Bladé J; Rosiñol L
Leukemia; 2018 Sep; 32(9):2082-2094. PubMed ID: 29795240
[No Abstract] [Full Text] [Related]
19. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma.
Ravi P; Kumar S; Larsen JT; Gonsalves W; Buadi F; Lacy MQ; Go R; Dispenzieri A; Kapoor P; Lust JA; Dingli D; Lin Y; Russell SJ; Leung N; Gertz MA; Kyle RA; Bergsagel PL; Rajkumar SV
Blood Cancer J; 2016 Jul; 6(7):e454. PubMed ID: 27471870
[TBL] [Abstract][Full Text] [Related]
20. Pseudohyperphosphatemia in a patient with incidentally identified progression of smoldering myeloma.
Francis ER; Chen F; Kidacki M; Miller R; Alkhasoneh M; Talamo G; Straub M; Klinefelter K; Kodali N; Zhu Y
Clin Chim Acta; 2018 Dec; 487():306-308. PubMed ID: 30315756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
